We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Guangzhou Pluslife Biotech Co., Ltd.

SEBIA

Sebia provides clinical protein electrophoresis equipment and reagents for in-vitro diagnostic testing, including sys... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

DNA Testing Assessed in Childhood Sickle-Cell Anemia Diagnosis

By LabMedica International staff writers
Posted on 21 Jul 2022
Print article
Image: Blood film of a patient with sickle cell/β 0 thalassemia compound heterozygosity shows one sickle cell, boat-shaped cells, target cells, three nucleated red cells, anisocytosis, poikilocytosis (Ke Xu, MD)
Image: Blood film of a patient with sickle cell/β 0 thalassemia compound heterozygosity shows one sickle cell, boat-shaped cells, target cells, three nucleated red cells, anisocytosis, poikilocytosis (Ke Xu, MD)

Sickle-cell disease (SCD) is the most common genetic disorder worldwide. SCD patients are homozygous for a recurrent mutation in the HBB-gene resulting in the substitution of a glutamic acid residue with a valine amino acid at position 6 of the beta globin protein (E6V).

The mutated protein, known as HbS, has a different electrical charge, which is exploited for the distinction of HbS from HbA by electrophoresis. The term SCD refers to all different genotypes that cause characteristic clinical syndrome, whereas sickle-cell anemia (SCA), the most prevalent form of SCD, refers to the homozygous form of SS, and the heterozygous compound forms such as S/β-thalassemia, SC disease refer to SCD.

Molecular Geneticists at the KU Leuven and University Hospitals Leuven (Leuven, Belgium) collaborating with their colleagues at the University of Kinshasa (Kinshasa, Democratic Republic of Congo) conducted a cross-sectional study from November 2016 to end October 2017 and 160 patients were included. The diagnosis in these patients was made by clinical suspicion associated with a positive Emmel test, occasionally people received hemoglobin electrophoresis and/or hemoglobin isoelectrofocusing.

For each patient, the team collected blood in two 4 mL EDTA tubes. They obtained a full blood cells count (red blood cells (RBC), white blood cells (WBC), platelets and reticulocytes). Biochemical analyses included lactate dehydrogenase (LDH), bilirubin, serum creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT). Hemoglobin electrophoresis was performed using the automated Minicap (Sebia, Norcross, GA, USA). DNA was extracted by the salting out method, and mutation analysis for the SCA mutation (E6V) was performed. Mutation analysis of the β-globin gene was accomplished by resequencing the coding exons and by Multiplex Ligation-dependent Probe Amplification (MLPA), in patients suspected for compound form of SCD Sβ-thalassemia.

The investigators reported that hemoglobin capillary electrophoresis suggested that 136 (85%) were homozygote SS, 13 (8.1%) were heterozygote (AS), and 11 (6.9%) were homozygote normal (AA). DNA testing confirmed these electrophoresis findings, with the exception of four patients, two AS in electrophoresis were found SS due to recent transfusion, and two SS in electrophoresis were found AS because they have compound heterozygous form S/β 0-thalassemia. The diagnosis of SCA was therefore wrongly ascertained with Emmel test in 15% of patients.

The authors concluded that their study revealed a high proportion of wrongly diagnosed SCA patients in a rural environment in Central Africa, and underlines the importance of a DNA test in addition to Hb electrophoresis in helping to clarify the diagnosis of SCA. Improving the skills of healthcare professionals in the clinical recognition of SCA in children remains a crucial step in the management of SCA, especially in rural area. The study was published on July 12, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
KU Leuven and University Hospitals Leuven 
University of Kinshasa 
Sebia 

Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
New
H.pylori Diagnostic Kit
Helicosign Dry
New
Blood Transfusion Safety Test
ABTest Card
New
Silver Supplier
Monkeypox Virus Real Time PCR Test
Monkeypox Virus Real Time PCR Detection Kit

Print article
SUGENTECH INC.

Channels

Clinical Chem.

view channel
Image: ELISA kit for liver-type fatty acid–binding protein (L-FABP). The level of L-FABP present in urine reflects the level of renal tubular dysfunction (Photo courtesy of Sekisui Medical Co)

Urinary Biomarkers Predict Weaning From Acute Dialysis Therapy

Acute kidney injury is associated with a higher risk of chronic kidney disease (CKD), end-stage renal disease, and long-term adverse cardiovascular effects. Critically ill patients with acute kidney injury... Read more

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.